Exparel 266 MG/20 ML vial 20ML
Ended Awarded
- Contract number
- SPE2DR26FRDH0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $40,133
Award facts
- Contract value 100% obligated
- $40,133.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. This firm fixed-price delivery order, valued at $40,133.04, was awarded on November 20, 2025, with an ultimate completion date of December 12, 2025. The award carries no set-aside designation, reflecting DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. EXPAREL is a specialty surgical product used for prolonged local anesthesia and pain management in surgical procedures, supporting the Department of Defense's medical supply requirements.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The underlying IDC, awarded on November 13, 2025, carries a $499.99 billion ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as one of multiple regional prime vendors within the broader $30.3 billion PPV-G GEN V acquisition strategy. This comprehensive contract framework authorizes the agency to issue delivery orders for a full range of pharmaceutical products, biologics, and medical consumables to support military healthcare facilities worldwide, enabling DMS Pharmaceutical Group to serve as a critical pharmaceutical supplier for Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FRDH0?
SPE2DR26FRDH0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 20, 2025.
How much is contract SPE2DR26FRDH0 worth?
The government has obligated $40,133 on SPE2DR26FRDH0.
Is contract SPE2DR26FRDH0 an order under another contract?
Yes. SPE2DR26FRDH0 is a delivery order under SPE2DR25D9143, an indefinite delivery contract.
Was contract SPE2DR26FRDH0 competed?
The extent of competition for SPE2DR26FRDH0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award